Advertisement

Human African Trypanosomiasis (HAT)

  • Pascal Lutumba
  • Enock Matovu
  • Marleen Boelaert
Chapter
Part of the Neglected Tropical Diseases book series (NTD)

Abstract

Human African trypanosomiasis (HAT) found only in sub-Saharan Africa is caused by the parasite Trypanosoma brucei which is transmitted by tsetse flies. Only two subspecies of T.brucei are pathogenic for humans: T.b. gambiense and T.b. rhodesiense. HAT is endemic in 36 sub-Saharan countries, and 98 % of all reported HAT cases are due to T. b. gambiense. Sixty-nine million persons in Africa are at risk of HAT. The number of HAT cases reported globally decreased fivefold in the last decade which has encouraged WHO to set a target to eliminate HAT as a public health problem by the year 2020, aiming for zero transmission by the year 2030. Tsetse flies do not lay eggs, but the female fly deposits a single mature larva in humid soil. The larva pupates and emerges as an adult fly 20–80 days later. A female fly produces only three to five larvae during her lifetime that typically lasts for 3 months, making the intrinsic growth rate of tsetse populations rather low. An infected tsetse fly injects the infective form of the parasites into the mammalian host when it feeds. These parasites undergo, and are able to switch, their antigenic variation of their variant surface glycoprotein (VSG) coat, allowing them to escape the host immune response. This phenomenon of antigenic variation makes the development of an effective vaccine unlikely. The disease affects mainly the lymphoid system, heart, lungs and brain manifesting as intermittent fever, general malaise, severe headache, joint pains and muscle aches, pruritus, urticaria or facial oedema. Lymphadenopathy is common with the classical Winterbottom’s sign. Patients with the meningo-encephalitic stage suffer continuous headaches with poor response to painkillers and show more specific neurological signs of the rather typical sleep disturbances. Diagnosis of HAT is a three-step procedure: (i) screening test to identify HAT suspects, (ii) confirmatory parasitological tests and (iii) staging. Treatment is based on the stage of illness, current options being pentamidine, suramin, melarsoprol, eflornithine and the nifurtimox-eflornithine combination therapy (NECT). Two strategies are used for the reduction or interruption of HAT transmission: elimination of the parasite reservoir and vector control. This last decade has seen several breakthroughs in clinical R&D for HAT, bringing new diagnostics and drugs to patient care, but effective and efficient implementation of these new tools in HAT control and proper treatment of patients will require further research.

Keywords

Human African trypanosomiasis Epidemiology Control Integration 

References

  1. Abd-Alla AM, Bergoin M, Parker AG, Maniania NK, Vlak JM, Bourtzis K, Boucias DG, Aksoy S (2013) Improving Sterile Insect Technique (SIT) for tsetse flies through research on their symbionts and pathogens. J Invertebr Pathol 112(Suppl):S2–S10PubMedPubMedCentralCrossRefGoogle Scholar
  2. Abel PM, Kiala G, Loa V, Behrend M, Musolf J, Fleischmann H, Theophile J, Krishna S, Stich A (2004) Retaking sleeping sickness control in Angola. Trop Med Int Health 9(1):141–148PubMedCrossRefGoogle Scholar
  3. Alirol E, Schrumpf D, Amici HJ, Riedel A, de Patoul C, Quere M, Chappuis F (2013) Nifurtimox-eflornithine combination therapy for second-stage gambiense human African trypanosomiasis: medecins sans frontieres experience in the Democratic Republic of the Congo. Clin Infect Dis 56(2):195–203PubMedCrossRefGoogle Scholar
  4. Artzrouni M, Gouteux JP (1996) Control strategies for sleeping sickness in Central Africa: a model-based approach. Trop Med Int Health 1(6):753–764PubMedCrossRefGoogle Scholar
  5. Artzrouni M, Gouteux JP (2001) A model of Gambian sleeping sickness with open vector populations. IMA J Math Appl Med Biol 18(2):99–117PubMedCrossRefGoogle Scholar
  6. Blum JA, Schmid C, Burri C, Hatz C, Olson C, Fungula B, Kazumba L, Mangoni P, Mbo F, Deo K, Mpanya A, Dala A, Franco JR, Pohlig G, Zellweger MJ (2009) Cardiac alterations in human African trypanosomiasis (T.b. gambiense) with respect to the disease stage and antiparasitic treatment. PLoS Negl Trop Dis 3(2):e383PubMedPubMedCentralCrossRefGoogle Scholar
  7. Bouyer J (2008) Does isometamidium chloride treatment protect tsetse flies from trypanosome infections during SIT campaigns? Med Vet Entomol 22(2):140–143PubMedCrossRefGoogle Scholar
  8. Bouyer J, Stachurski F, Kabore I, Bauer B, Lancelot R (2007) Tsetse control in cattle from pyrethroid footbaths. Prev Vet Med 78(3–4):223–238, available from: PM:17126431PubMedCrossRefGoogle Scholar
  9. Brun R, Blum J, Chappuis F, Burri C (2010) Human African trypanosomiasis. Lancet 375(9709):148–159PubMedCrossRefGoogle Scholar
  10. Bruneel H, van den Eeckhout A, Molisho D, Burke J, Degroof D, Pepin J (1994) Control of trypanosoma gambiense trypanosomiasis. Evaluation of a strategy based on the treatment of serologically suspected cases with a single dose of diminazene. Ann Soc Belg Med Trop 74(3):203–215PubMedGoogle Scholar
  11. Buscher P, Deborggraeve S (2015) How can molecular diagnostics contribute to the elimination of human African trypanosomiasis? Expert Rev Mol Diagn 15(5):607–615PubMedCrossRefGoogle Scholar
  12. Buscher P, Gilleman Q, Lejon V (2013) Rapid diagnostic test for sleeping sickness. N Engl J Med 368(11):1069–1070PubMedCrossRefGoogle Scholar
  13. Buscher P, Mertens P, Leclipteux T, Gilleman Q, Jacquet D, Mumba-Ngoyi D, Pyana PP, Boelaert M, Lejon V (2014) Sensitivity and specificity of HAT Sero-K-SeT, a rapid diagnostic test for serodiagnosis of sleeping sickness caused by Trypanosoma brucei gambiense: a case-control study. Lancet Glob Health 2(6):e359–e363PubMedCrossRefGoogle Scholar
  14. CDC. Life cycle of Trypanosoma spp. Available from: http://www.cdc.gov/dpdx/trypanosomiasisAfrican/index.html. Accessed 28 Jul 2015
  15. Denecke K (1941) Menschen pathogene Trypanosome des Hundes auf Fernando-Po. Ein beitrag zur Epidemiologie der Schlafkrankheit. Arch Hyg Bakteriol 166:331–348Google Scholar
  16. Ebeja AK, Lutumba P, Molisho D, Kegels G, Miaka Mia BC, Boelaert M (2003) Sleeping sickness in the region of the town of Kinshasa: a retrospective analysis during the surveillance period 1996–2000. Trop Med Int Health 8(10):949–955PubMedCrossRefGoogle Scholar
  17. Fevre EM, Wissmann BV, Welburn SC, Lutumba P (2008) The burden of human African trypanosomiasis. PLoS Negl Trop Dis 2(12):e333PubMedPubMedCentralCrossRefGoogle Scholar
  18. Franco JR, Simarro PP, Diarra A, Jannin JG (2014a) Epidemiology of human African trypanosomiasis. Clin Epidemiol 6:257–275PubMedPubMedCentralGoogle Scholar
  19. Franco JR, Simarro PP, Diarra A, Ruiz-Postigo JA, Jannin JG (2014b) The journey towards elimination of gambiense human African trypanosomiasis: not far, nor easy. Parasitology 141(6):748–760PubMedCrossRefGoogle Scholar
  20. Frezil JL, Coulm J (1977) Present concept of strategy against sleeping sickness in the Democratic Republic of Congo. Ann Soc Belg Med Trop 57(4–5):315–322PubMedGoogle Scholar
  21. Gouteux JP, Lancien J (1986) The pyramidal trap for collecting and controlling tsetse flies (diptera: glossinidae). Comparative trials and description of new collecting technics. Trop Med Parasitol 37(1):61–66PubMedGoogle Scholar
  22. Gouteux JP, Sinda D (1990) Community participation in the control of tsetse flies. Large scale trials using the pyramid trap in the Congo. Trop Med Parasitol 41(1):49–55PubMedGoogle Scholar
  23. Gouteux JP, Challier A, Laveissiere C, Couret D (1982) The use of screens in the anti-tsetse campaign in the forest zone. Tropenmed Parasitol 33(3):163–168PubMedGoogle Scholar
  24. Gouteux JP, Lancien J, Noireau F, Sinda D (1986) Control of vectors by trapping and its impact on sleeping sickness in a zone of high density of Glossina fuscipes quanzensis (Lefini River, People’s Republic of the Congo). Trop Med Parasitol 37(2):101–104PubMedGoogle Scholar
  25. Gouteux JP, Bansimba P, Noireau F, Frezil JL (1987) Cost of the individual treatment of trypanosoma brucei gambiense trypanosomiasis in a focus of infection in Niari (Congo). Med Trop (Mars) 47(1):61–63Google Scholar
  26. Hasker E, Lumbala C, Mbo F, Mpanya A, Kande V, Lutumba P, Boelaert M (2011) Health care-seeking behaviour and diagnostic delays for human African trypanosomiasis in the Democratic Republic of the Congo. Trop Med Int Health 16(7):869–874PubMedCrossRefGoogle Scholar
  27. Hasker E, Lutumba P, Chappuis F, Kande V, Potet J, De Weggheleire A, Kambo C, Depoortere E, Pecoul B, Boelaert M (2012) Human african trypanosomiasis in the Democratic Republic of the Congo: a looming emergency? PLoS Negl Trop Dis 6(12):e1950PubMedPubMedCentralCrossRefGoogle Scholar
  28. Herder S, Simo G, Nkinin S, Njiokou F (2002) Identification of trypanosomes in wild animals from southern Cameroon using the polymerase chain reaction (PCR). Parasite 9(4):345–349PubMedCrossRefGoogle Scholar
  29. Hide G (1999) History of sleeping sickness in East Africa. Clin Microbiol Rev 12(1):112–125PubMedPubMedCentralGoogle Scholar
  30. Hide G, Tait A, Maudlin I, Welburn SC (1996) The origins, dynamics and generation of Trypanosoma brucei rhodesiense epidemics in East Africa. Parasitol Today 12(2):50–55PubMedCrossRefGoogle Scholar
  31. Ilboudo H, Bras-Goncalves R, Camara M, Flori L, Camara O, Sakande H, Leno M, Petitdidier E, Jamonneau V, Bucheton B (2014) Unravelling human trypanotolerance: IL8 is associated with infection control whereas IL10 and TNF alpha are associated with subsequent disease development. PLoS Pathog 10(11):e1004469PubMedPubMedCentralCrossRefGoogle Scholar
  32. Jacobs RT, Nare B, Wring SA, Orr MD, Chen D, Sligar JM, Jenks MX, Noe RA, Bowling TS, Mercer LT, Rewerts C, Gaukel E, Owens J, Parham R, Randolph R, Beaudet B, Bacchi CJ, Yarlett N, Plattner JJ, Freund Y, Ding C, Akama T, Zhang YK, Brun R, Kaiser M, Scandale I, Don R (2011) SCYX-7158, an orally-active benzoxaborole for the treatment of stage 2 human African trypanosomiasis. PLoS Negl Trop Dis 5(6):e1151PubMedPubMedCentralCrossRefGoogle Scholar
  33. Jamonneau V, Ravel S, Koffi M, Kaba D, Zeze DG, Ndri L, Sane B, Coulibaly B, Cuny G, Solano P (2004) Mixed infections of trypanosomes in tsetse and pigs and their epidemiological significance in a sleeping sickness focus of Cote d’Ivoire. Parasitology 129(Pt 6):693–702PubMedCrossRefGoogle Scholar
  34. Jamonneau V, Ilboudo H, Kabore J, Kaba D, Koffi M, Solano P, Garcia A, Courtin D, Laveissiere C, Lingue K, Buscher P, Bucheton B (2012) Untreated human infections by trypanosoma brucei gambiense are not 100% fatal. PLoS Negl Trop Dis 6(6):e1691PubMedPubMedCentralCrossRefGoogle Scholar
  35. Jamonneau V, Camara O, Ilboudo H, Peylhard M, Koffi M, Sakande H, N’Dri L, Sanou D, Dama E, Camara M, Lejon V (2015) Accuracy of individual rapid tests for serodiagnosis of gambiense sleeping sickness in West Africa. PLoS Negl Trop Dis 9(2):e0003480PubMedPubMedCentralCrossRefGoogle Scholar
  36. Kennedy PG (2008) Diagnosing central nervous system trypanosomiasis: two stage or not to stage? Trans R Soc Trop Med Hyg 102(4):306–307PubMedCrossRefGoogle Scholar
  37. Kennedy PG (2013) Clinical features, diagnosis, and treatment of human African trypanosomiasis (sleeping sickness). Lancet Neurol 12(2):186–194PubMedCrossRefGoogle Scholar
  38. Kgori PM, Modo S, Torr SJ (2006) The use of aerial spraying to eliminate tsetse from the Okavango Delta of Botswana. Acta Trop 99(2–3):184–199PubMedCrossRefGoogle Scholar
  39. Lancien J (1991) Campaign against sleeping sickness in South-West Uganda by trapping tsetse flies. Ann Soc Belg Med Trop 71(Suppl 1):35–47PubMedGoogle Scholar
  40. Laveissiere C, Sane B, Meda HA (1994) Measurement of risk in endemic areas of human African trypanosomiasis in Cote d’Ivoire. Trans R Soc Trop Med Hyg 88(6):645–648PubMedCrossRefGoogle Scholar
  41. Lindh JM, Goswami P, Blackburn RS, Arnold SE, Vale GA, Lehane MJ, Torr SJ (2012) Optimizing the colour and fabric of targets for the control of the tsetse fly glossina fuscipes fuscipes. PLoS Negl Trop Dis 6(5):e1661PubMedPubMedCentralCrossRefGoogle Scholar
  42. Lundkvist GB, Kristensson K, Bentivoglio M (2004) Why trypanosomes cause sleeping sickness. Physiology (Bethesda) 19:198–206CrossRefGoogle Scholar
  43. Lutumba P, Robays J, Miaka Mia BC, Mesu VK, Molisho D, Declercq J, Van der Veken W, Meheus F, Jannin J, Boelaert M (2005) Trypanosomiasis control, Democratic Republic of Congo, 1993–2003. Emerg Infect Dis 11(9):1382–1388PubMedPubMedCentralCrossRefGoogle Scholar
  44. Lutumba P, Makieya E, Shaw A, Meheus F, Boelaert M (2007) Human African trypanosomiasis in a rural community, Democratic Republic of Congo. Emerg Infect Dis 13(2):248–254PubMedPubMedCentralCrossRefGoogle Scholar
  45. Magez S, Caljon G, Tran T, Stijlemans B, Radwanska M (2010) Current status of vaccination against African trypanosomiasis. Parasitology 137(14):2017–2027PubMedCrossRefGoogle Scholar
  46. Magnus E, Vervoort T, Van Meirvenne N (1978) A card-agglutination test with stained trypanosomes (C.A.T.T.) for the serological diagnosis of T. B. gambiense trypanosomiasis. Ann Soc Belg Med Trop 58(3):169–176PubMedGoogle Scholar
  47. Malvy D, Chappuis F (2011) Sleeping sickness. Clin Microbiol Infect 17(7):986–995PubMedCrossRefGoogle Scholar
  48. Mitashi P, Hasker E, Lejon V, Kande V, Muyembe JJ, Lutumba P, Boelaert M (2012) Human african trypanosomiasis diagnosis in first-line health services of endemic countries, a systematic review. PLoS Negl Trop Dis 6(11):e1919PubMedPubMedCentralCrossRefGoogle Scholar
  49. Mitashi P, Hasker E, Ngoyi DM, Pyana PP, Lejon V, Van der Veken W, Lutumba P, Buscher P, Boelaert M, Deborggraeve S (2013) Diagnostic accuracy of loopamp trypanosoma brucei detection kit for diagnosis of human African trypanosomiasis in clinical samples. PLoS Negl Trop Dis 7(10):e2504PubMedPubMedCentralCrossRefGoogle Scholar
  50. Mitashi P, Hasker E, Mbo F, Van Geertruyden JP, Kaswa M, Lumbala C, Boelaert M, Lutumba P (2015) Integration of diagnosis and treatment of sleeping sickness in primary healthcare facilities in the Democratic Republic of the Congo. Trop Med Int Health 20(1):98–105PubMedCrossRefGoogle Scholar
  51. Molyneux DH (1973) Isolation of trypanosoma (trypanozoon) brucei gambiense in rabbits by the intratesticular inoculation technique. Ann Trop Med Parasitol 67(4):391–397PubMedGoogle Scholar
  52. Moore A, Richer M (2001) Re-emergence of epidemic sleeping sickness in southern Sudan. Trop Med Int Health 6(5):342–347PubMedCrossRefGoogle Scholar
  53. Mpanya A, Hendrickx D, Vuna M, Kanyinda A, Lumbala C, Tshilombo V, Mitashi P, Luboya O, Kande V, Boelaert M, Lefevre P, Lutumba P (2012) Should I get screened for sleeping sickness? A qualitative study in Kasai province, Democratic Republic of Congo. PLoS Negl Trop Dis 6(1):e1467PubMedPubMedCentralCrossRefGoogle Scholar
  54. Mugasa CM, Katiti D, Boobo A, Lubega GW, Schallig HD, Matovu E (2014) Comparison of nucleic acid sequence-based amplification and loop-mediated isothermal amplification for diagnosis of human African trypanosomiasis. Diagn Microbiol Infect Dis 78(2):144–148PubMedCrossRefGoogle Scholar
  55. Murray CJ et al (2012) Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the global burden of disease study 2010. Lancet 380(9859):2197–2223PubMedCrossRefGoogle Scholar
  56. Nkinin SW, Njiokou F, Penchenier L, Grebaut P, Simo G, Herder S (2002) Characterization of trypanosoma brucei s.l. subspecies by isoenzymes in domestic pigs from the Fontem sleeping sickness focus of Cameroon. Acta Trop 81(3):225–232PubMedCrossRefGoogle Scholar
  57. Paquet C, Castilla J, Mbulamberi D, Beaulieu MF, Gastellu Etchegorry MG, Moren A (1995) Trypanosomiasis from trypanosoma brucei gambiense in the center of north-west Uganda. Evaluation of 5 years of control (1987–1991). Bull Soc Pathol Exot 88(1):38–41PubMedGoogle Scholar
  58. Pepin J, Meda HA (2001) The epidemiology and control of human African trypanosomiasis. Adv Parasitol 49:71–132PubMedCrossRefGoogle Scholar
  59. Pepin J, Milord F (1994) The treatment of human African trypanosomiasis. Adv Parasitol 33:1–47PubMedCrossRefGoogle Scholar
  60. Politi C, Carrin G, Evans D, Kuzoe FA, Cattand PD (1995) Cost-effectiveness analysis of alternative treatments of African gambiense trypanosomiasis in Uganda. Health Econ 4(4):273–287PubMedCrossRefGoogle Scholar
  61. Priotto G, Kasparian S, Mutombo W, Ngouama D, Ghorashian S, Arnold U, Ghabri S, Baudin E, Buard V, Kazadi-Kyanza S, Ilunga M, Mutangala W, Pohlig G, Schmid C, Karunakara U, Torreele E, Kande V (2009) Nifurtimox-eflornithine combination therapy for second-stage African trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial. Lancet 374(9683):56–64PubMedCrossRefGoogle Scholar
  62. Robays J, Bilengue MM, Van der Stuyft P, Boelaert M (2004) The effectiveness of active population screening and treatment for sleeping sickness control in the Democratic Republic of Congo. Trop Med Int Health 9(5):542–550PubMedCrossRefGoogle Scholar
  63. Robays J, Lefevre P, Lutumba P, Lubanza S, Kande Betu KMV, Van der Stuyft P, Boelaert M (2007) Drug toxicity and cost as barriers to community participation in HAT control in the Democratic Republic of Congo. Trop Med Int Health 12(2):290–298PubMedCrossRefGoogle Scholar
  64. Schmid C, Kuemmerle A, Blum J, Ghabri S, Kande V, Mutombo W, Ilunga M, Lumpungu I, Mutanda S, Nganzobo P, Tete D, Mubwa N, Kisala M, Blesson S, Mordt OV (2012) In-hospital safety in field conditions of nifurtimox eflornithine combination therapy (NECT) for T. b. gambiense sleeping sickness. PLoS Negl Trop Dis 6(11):e1920PubMedPubMedCentralCrossRefGoogle Scholar
  65. Shaw AP, Tirados I, Mangwiro CT, Esterhuizen J, Lehane MJ, Torr SJ, Kovacic V (2015) Costs of using “tiny targets” to control glossina fuscipes fuscipes, a vector of gambiense sleeping sickness in Arua District of Uganda. PLoS Negl Trop Dis 9(3):e0003624PubMedPubMedCentralCrossRefGoogle Scholar
  66. Simarro PP, Sima FO, Mir M, Mateo MJ, Roche J (1991) Control of human African trypanosomiasis in Luba in equatorial Guinea: evaluation of three methods. Bull World Health Organ 69(4):451–457PubMedPubMedCentralGoogle Scholar
  67. Simarro PP, Franco JR, Asumu PN (2001) Has the focus of human African trypanosomiasis in Luba, Equatorial Guinea been eradicated? Med Trop (Mars) 61(4–5):441–444Google Scholar
  68. Simarro PP, Cecchi G, Paone M, Franco JR, Diarra A, Ruiz JA, Fevre EM, Courtin F, Mattioli RC, Jannin JG (2010) The atlas of human African trypanosomiasis: a contribution to global mapping of neglected tropical diseases. Int J Health Geogr 9:57PubMedPubMedCentralCrossRefGoogle Scholar
  69. Simarro PP, Cecchi G, Franco JR, Paone M, Diarra A, Ruiz-Postigo JA, Fevre EM, Mattioli RC, Jannin JG (2012a) Estimating and mapping the population at risk of sleeping sickness. PLoS Negl Trop Dis 6(10):e1859PubMedPubMedCentralCrossRefGoogle Scholar
  70. Simarro PP, Franco JR, Cecchi G, Paone M, Diarra A, Ruiz Postigo JA, Jannin JG (2012b) Human African trypanosomiasis in non-endemic countries (2000–2010). J Travel Med 19(1):44–53PubMedCrossRefGoogle Scholar
  71. Sternberg JM (2004) Human African trypanosomiasis: clinical presentation and immune response. Parasite Immunol 26(11–12):469–476PubMedCrossRefGoogle Scholar
  72. Sternberg JM, Gierlinski M, Bieler S, Ferguson MA, Ndung’u JM (2014) Evaluation of the diagnostic accuracy of prototype rapid tests for human African trypanosomiasis. PLoS Negl Trop Dis 8(12):e3373PubMedPubMedCentralCrossRefGoogle Scholar
  73. Tarral A, Blesson S, Mordt OV, Torreele E, Sassella D, Bray MA, Hovsepian L, Evene E, Gualano V, Felices M, Strub-Wourgaft N (2014) Determination of an optimal dosing regimen for fexinidazole, a novel oral drug for the treatment of human African trypanosomiasis: first-in-human studies. Clin Pharmacokinet 53(6):565–580PubMedPubMedCentralCrossRefGoogle Scholar
  74. Torreele E, Bourdin TB, Tweats D, Kaiser M, Brun R, Mazue G, Bray MA, Pecoul B (2010) Fexinidazole–a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness. PLoS Negl Trop Dis 4(12):e923, available from: PM:21200426PubMedPubMedCentralCrossRefGoogle Scholar
  75. Urech K, Neumayr A, Blum J (2011) Sleeping sickness in travelers – do they really sleep? PLoS Negl Trop Dis 5(11):e1358PubMedPubMedCentralCrossRefGoogle Scholar
  76. Van Hoof LM (1947) Observations on trypanosomiasis in the Belgian Congo. Trans R Soc Trop Med Hyg 40(6):728–761Google Scholar
  77. Van Nieuwenhove S, Betu-Ku-Mesu VK, Diabakana PM, Declercq J, Bilenge CM (2001) Sleeping sickness resurgence in the DRC: the past decade. Trop Med Int Health 6(5):335–341PubMedCrossRefGoogle Scholar
  78. Vreysen MJ (2001) Principles of area-wide integrated tsetse fly control using the sterile insect technique. Med Trop (Mars) 61(4–5):397–411Google Scholar
  79. Welburn SC, Fevre EM, Coleman PG, Odiit M, Maudlin I (2001) Sleeping sickness: a tale of two diseases. Trends Parasitol 17(1):19–24PubMedCrossRefGoogle Scholar
  80. WHO (1998) Control and surveillance of African trypanosomiasis. Report of a WHO expert committee. World Health Organ Tech Rep Ser 881:I–114Google Scholar
  81. WHO (2013) Control and surveillance of human African trypanosomiasis. World Health Organ Tech Rep Ser 984:1–237Google Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  • Pascal Lutumba
    • 1
    • 2
  • Enock Matovu
    • 3
  • Marleen Boelaert
    • 4
  1. 1.Department of EpidemiologyInstitut National de Recherche Biomédicale (INRB)KinshasaDemocratic Republic of Congo
  2. 2.Tropical Medicine Department, Faculty of MedicineKinshasa University (UNIKIN)KinshasaDemocratic Republic of Congo
  3. 3.College of Veterinary Medicine, Animal Resources and BiosecurityMakerere UniversityKampalaUganda
  4. 4.Department of Public HealthInstitute of Tropical Medicine–AntwerpAntwerpBelgium

Personalised recommendations